Novo Nordisk plans Phase 3 trials of oral, injectable amycretin

Novo Nordisk plans to go straight to Phase 3 with its experimental weight loss drug amycretin in the first quarter of 2026, the Danish drug giant said Thursday. The rush to late-stage testing signals Novo' ...

Related Posts

Researchers reveal mixed results from vaccine for cocai...

May 21, 2025  0

InflaRx cans Gohibic development after skin disease tri...

May 28, 2025  0

Generics giant Teva turns to branded drugs R&D for its ...

Jun 5, 2025  0

Comments

Name

Email

Comment

Post Comment